UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1271-7
Program Prior Authorization/Notification
Medication Vitrakvi® (larotrectinib)
P&T Approval Date 1/2019, 1/2020, 1/2021, 1/2022, 1/2023, 1/2024, 1/2025
Effective Date 4/1/2025
1. Background:
Vitrakvi® (larotrectinib) is a kinase inhibitor indicated for the treatment of adult and pediatric
patients with solid tumors that:
• have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired
resistance mutation,
• are metastatic or where surgical resection is likely to result in severe morbidity, and
• have no satisfactory alternative treatments or that have progressed following treatment.
This indication is approved under accelerated approval based on overall response rate and
duration of response. Continued approval for this indication may be contingent upon verification
and description of clinical benefit in confirmatory trials.
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Vitrakvi will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Solid Tumors
1. Initial Authorization
a. Vitrakvi will be approved based on all of the following criteria:
(1) Presence of a solid tumor
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
(2) Disease is positive for neurotrophic receptor tyrosine kinase (NTRK) gene fusion
(e.g. ETV6-NTRK3, TPM3-NTRK1, LMNA-NTRK1, etc.)
-AND-
(3) Disease is without a known acquired resistance mutation (e.g., TRKA G595R,
G623R, G696A, F617L.).
-AND-
(4) Disease is one of the following:
(a) Metastatic
(b) Unresectable
Authorization will be issued for 12 months.
2. Reauthorization
a. Vitrakvi will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Vitrakvi therapy
Authorization will be issued for 12 months.
C. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category of
Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Vitrakvi [package insert]. Bayer HealthCare Pharmaceuticals Inc.: Whippany, NJ; November
2023.
© 2025 UnitedHealthcare Services, Inc.
2
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
http://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed November
27, 2024.
Program Prior Authorization/Notification - Vitrakvi® (larotrectinib)
Change Control
1/2019 New program.
1/2020 Annual review. Added general NCCN recommendations for use criteria.
Updated references.
1/2021 Annual review. Removed listed solid tumor examples since list was not all
inclusive. No change to coverage criteria. Updated references.
1/2022 Annual review with no change to clinical criteria. Updated resistant
mutation examples to reflect package insert. Updated references.
1/2023 Annual review. Removed criteria requiring previous treatment progression
or no alternative therapy based on first line recommendations per NCCN
for certain cancers. Added state mandate footnote. Updated reference.
1/2024 Annual review with no changes to clinical criteria. Updated references.
1/2025 Annual review with no changes to clinical criteria. Updated references.
© 2025 UnitedHealthcare Services, Inc.
3